4D Molecular Therapeutics (FDMT) Business News Nov. 06, 2025, 11:23 UTC 4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants Full text
Register to leave comments News bot Nov. 11, 2025, 5:03 p.m. 📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical